Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 05/27 10:03:19 pm
56.48 USD   +0.16%
05/27 MERCK : Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir..
05/26 MERCK : Corporate Social Responsibility Related News Releases and St..
05/24 MERCK : Announces Third-Quarter 2016 Dividend
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Lawsuit Claims Merck Overstated Mumps Vaccine Effectiveness

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/22/2012 | 07:32pm CEST
   By Jon Kamp 
 

Two former Merck & Co. Inc. (MRK) employees have sued the company in federal court alleging Merck overstated the effectiveness of a mumps vaccine for which the U.S. government paid hundreds of millions of dollars.

Merck--which stressed that none of these allegations relate to the safety of its product--said the lawsuit is "completely without merit", and that it plans to "vigorously defend itself." The Whitehouse Station, N.J., drug maker also noted that the U.S. Department of Justice has thus far declined to participate in the case after its own two-year probe.

Mumps is a contagious disease that causes symptoms like fever, headache and swollen salivary glands. It was a common illness for kids and young adults before childhood vaccinations became common decades ago, according to the Centers for Disease Control and Prevention, although there were outbreaks in 2006 and 2009. The agency says vaccines are the best way to prevent mumps.

Merck introduced the first vaccine 45 years ago, and since the 1970s it's been part of a combination product that also immunizes children against rubella and measles. According to the lawsuit--filed by former Merck virologists Stephen Krahling and Joan Wlochowski--the company allegedly defrauded the U.S. for more than a decade by hiding the fact the vaccine had become less effective.

As a result, the former employees say the government has long paid for a product that doesn't live up to Merck's claims. The lawsuit seeks a judgment against Merck equal to three times the damages suffered by the U.S., plus the maximum allowable award for the former employees under federal whistleblower laws.

The suit was first filed in 2010 in the U.S. District Court for the Eastern District of Pennsylvania. It was unsealed Thursday after the government declined to get involved in the case.

Merck confirmed Krahling and Wlochowski were former employees, but it said they haven't worked at the company for a decade.

"It's important to understand that none of the allegations in the complaint relate to the safety of M-M-R II"--the vaccine in question--"and we remain confident that M-M-R II helps protect against measles, mumps and rubella as described in the labeling for the vaccine," Merck said in a statement.

"M-M-R II continues to be recommended for routine administration to children by public health authorities around the world, including the U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration," the company said.

Merck doesn't specifically break out sales for the vaccine, but the company reported combined U.S. sales of $1.1 billion last year for that product and two other childhood vaccines. Merck shares recently traded up 1.9% to $40.19 and have risen 6.6% this year.

Write to Jon Kamp at jon.kamp@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MERCK & CO., INC.
05/27 MERCK & CO., INC. : Submission of Matters to a Vote of Security Holders (form 8-..
05/27 MERCK : Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazopr..
05/26 MERCK : Corporate Social Responsibility Related News Releases and Story Ideas fo..
05/24 MERCK : Announces Third-Quarter 2016 Dividend
05/24 MERCK : to Present at the UBS Global Healthcare Conference
05/24 MSD ANIMAL HEALTH : Receives Marketing Approval from European Medicines Agency f..
05/24 MERCK : Announces FDA Accepts Samsung Bioepis’ Biologics License Applicati..
05/23 MERCK : Foundation Announces the Alliance to Advance Patient-Centered Cancer Car..
05/23DJGermany's Bayer Offers $62 Billion in Cash for Monsanto
05/19DJGermany's Bayer Breaks With Caution in Monsanto Bid
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials